These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 26093201)

  • 21. Neisseria meningitidis factor H-binding protein fHbp: a key virulence factor and vaccine antigen.
    Seib KL; Scarselli M; Comanducci M; Toneatto D; Masignani V
    Expert Rev Vaccines; 2015 Jun; 14(6):841-59. PubMed ID: 25704037
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MATS: Global coverage estimates for 4CMenB, a novel multicomponent meningococcal B vaccine.
    Medini D; Stella M; Wassil J
    Vaccine; 2015 May; 33(23):2629-36. PubMed ID: 25882169
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of Serogroup B Meningococcal Vaccines in Adolescents and Young Adults: Recommendations of the Advisory Committee on Immunization Practices, 2015.
    MacNeil JR; Rubin L; Folaranmi T; Ortega-Sanchez IR; Patel M; Martin SW
    MMWR Morb Mortal Wkly Rep; 2015 Oct; 64(41):1171-6. PubMed ID: 26492381
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of Serogroup B Meningococcal Vaccines in Persons Aged ≥10 Years at Increased Risk for Serogroup B Meningococcal Disease: Recommendations of the Advisory Committee on Immunization Practices, 2015.
    Folaranmi T; Rubin L; Martin SW; Patel M; MacNeil JR;
    MMWR Morb Mortal Wkly Rep; 2015 Jun; 64(22):608-12. PubMed ID: 26068564
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Updated Recommendations for Use of MenB-FHbp Serogroup B Meningococcal Vaccine - Advisory Committee on Immunization Practices, 2016.
    Patton ME; Stephens D; Moore K; MacNeil JR
    MMWR Morb Mortal Wkly Rep; 2017 May; 66(19):509-513. PubMed ID: 28520709
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevention of group B meningococcal disease by vaccination: a difficult task.
    Thomas M
    N Z Med J; 2004 Aug; 117(1200):U1016. PubMed ID: 15475986
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Emerging experience with meningococcal serogroup B protein vaccines.
    Toneatto D; Pizza M; Masignani V; Rappuoli R
    Expert Rev Vaccines; 2017 May; 16(5):433-451. PubMed ID: 28375029
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Community outbreak of serogroup B invasive meningococcal disease in Beaujolais, France, February to June 2016: from alert to targeted vaccination.
    Thabuis A; Tararbit K; Taha MK; Dejour-Salamanca D; Ronin V; Parent du Chatelet I; Spaccaferri G
    Euro Surveill; 2018 Jul; 23(28):. PubMed ID: 30017022
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recent developments in vaccines to prevent meningococcal serogroup B infections.
    Vermont CL; van den Dobbelsteen GP; de Groot R
    Curr Opin Mol Ther; 2003 Feb; 5(1):33-8. PubMed ID: 12669468
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of meningococcal group B OMV vaccines, beyond their brief.
    Petousis-Harris H
    Hum Vaccin Immunother; 2018 May; 14(5):1058-1063. PubMed ID: 29048985
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vaccines for prevention of group B meningococcal disease: Not your father's vaccines.
    Harrison LH
    Vaccine; 2015 Nov; 33 Suppl 4():D32-8. PubMed ID: 26116255
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serogroup B Meningococcal Disease Vaccine Recommendations at a University, New Jersey, USA, 2016.
    Soeters HM; Dinitz-Sklar J; Kulkarni PA; MacNeil JR; McNamara LA; Zaremski E; Chang HY; Lujan E; Granoff D; Lasky M; Montana B
    Emerg Infect Dis; 2017 May; 23(5):867-869. PubMed ID: 28418307
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Outer-membrane-vesicle vaccines: old but not forgotten.
    Stephens DS
    Lancet Infect Dis; 2011 Jun; 11(6):421-2. PubMed ID: 21489883
    [No Abstract]   [Full Text] [Related]  

  • 34. Meningococcal group B vaccines.
    Findlow J
    Hum Vaccin Immunother; 2013 Jun; 9(6):1387-8. PubMed ID: 23732894
    [TBL] [Abstract][Full Text] [Related]  

  • 35. First Use of a Serogroup B Meningococcal Vaccine in the US in Response to a University Outbreak.
    McNamara LA; Shumate AM; Johnsen P; MacNeil JR; Patel M; Bhavsar T; Cohn AC; Dinitz-Sklar J; Duffy J; Finnie J; Garon D; Hary R; Hu F; Kamiya H; Kim HJ; Kolligian J; Neglia J; Oakley J; Wagner J; Wagner K; Wang X; Yu Y; Montana B; Tan C; Izzo R; Clark TA
    Pediatrics; 2015 May; 135(5):798-804. PubMed ID: 25917990
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Meningococcal disease: a review on available vaccines and vaccines in development.
    Bröker M; Fantoni S
    Minerva Med; 2007 Oct; 98(5):575-89. PubMed ID: 18043565
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effectiveness of a vaccination programme for an epidemic of meningococcal B in New Zealand.
    Arnold R; Galloway Y; McNicholas A; O'Hallahan J
    Vaccine; 2011 Sep; 29(40):7100-6. PubMed ID: 21803101
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Meningococcal vaccines: from polysaccharide to conjugate vaccines].
    Cohen R; Levy C
    Arch Pediatr; 2012 Sep; 19 Suppl 2():S61-4. PubMed ID: 22883368
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Frequent capsule switching in 'ultra-virulent' meningococci - Are we ready for a serogroup B ST-11 complex outbreak?
    Lucidarme J; Lekshmi A; Parikh SR; Bray JE; Hill DM; Bratcher HB; Gray SJ; Carr AD; Jolley KA; Findlow J; Campbell H; Ladhani SN; Ramsay ME; Maiden MCJ; Borrow R
    J Infect; 2017 Aug; 75(2):95-103. PubMed ID: 28579305
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Protecting UK adolescents and adults against meningococcal serogroup B disease.
    Vyse A; Ellsbury G; Madhava H
    Expert Rev Vaccines; 2018 Mar; 17(3):229-237. PubMed ID: 29374982
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.